Molecular Signatures in Ductal Carcinoma In Situ (DCIS): A Systematic Review and Meta-Analysis.
Fiche publication
Date publication
mars 2023
Journal
Journal of clinical medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MATHELIN Carole
Tous les auteurs :
Ouattara D, Mathelin C, Özmen T, Lodi M
Lien Pubmed
Résumé
Adjuvant radiotherapy (RT) after breast-conserving surgery (BCS) for ductal carcinoma in situ (DCIS) is debated as benefits are inconstant. Molecular signatures for DCIS have been developed to stratify the risk of local recurrence (LR) and therefore guide the decision of RT.
Mots clés
de-escalation, ductal carcinoma in situ, local recurrence, molecular assay, precision medicine, radiotherapy
Référence
J Clin Med. 2023 03 3;12(5):